Money
Filter News
Found 84,377 articles
-
Following GSK’s lead, Pfizer plans to lower its interest in Haleon from 32% to approximately 24%, with the sale of 630 million ordinary shares in the consumer healthcare spinoff.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
TCBP Announces Exercise of Series D Warrants For Cash
3/18/2024
TC BioPharm PLC announced that an institutional investor has exercised cash only warrants represented 623,750 American Depository Shares at an exercise price of $2.02.
-
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas - March 18, 2024
3/18/2024
CytomX Therapeutics, Inc. today announced that the first clinical candidate in its TCB agreement with Astellas has entered into GLP toxicology studies which triggers a $5 million payment to CytomX.
-
ConKay Medical Systems Raises $1.8M in Oversubscribed Seed Funding Round
3/18/2024
ConKay Medical Systems, a medtech start-up company developing a unique device for treating patients suffering from valvular regurgitation, has closed an oversubscribed $1.8M seed round.
-
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
3/18/2024
Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.
-
Madrigal Pharmaceuticals Announces Proposed Public Offering - March 18, 2024
3/18/2024
Madrigal Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering of $500 million in shares of its common stock and pre-funded warrants to purchase common stock.
-
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
3/18/2024
AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.* Expanding the savings programs will help make its inhalers more affordable to the most vulnerable patients living with asthma and chronic obstructive pulmonary disease, including those who are uninsured and underinsured.
-
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
3/18/2024
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a $175 million five-year, term loan facility with Hercules Capital, Inc.
-
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - March 18, 2024
3/18/2024
Annexon, Inc. announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan.
-
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
3/18/2024
Acurx Pharmaceuticals, Inc. announced certain financial and operational results for the fourth quarter and full year ended December 31, 2023.
-
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
3/18/2024
Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported financial results for the fourth quarter and year ended December 31, 2023.
-
Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023
3/18/2024
Daxor Corporation, the global leader in blood volume measurement technology, announces the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2023.
-
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - March 18, 2024
3/18/2024
EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.
-
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
3/18/2024
BiomX Inc. announced the closing of its previously announced acquisition of Adaptive Phage Therapeutics, Inc. and its previously announced $50 million private placement to certain institutional accredited investors, which was led by affiliates of Deerfield Management Company and the AMR Action Fund, and additional investors including the Cystic Fibrosis Foundation, OrbiMed and Nantahala Capital.
-
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
3/18/2024
Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced fourth quarter and full year financial results for the period ended December 31, 2023, and an overview of the Company’s progress.
-
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
3/18/2024
Outlook Therapeutics, Inc. announced that it has closed its previously announced private placement, for upfront gross proceeds of approximately $60 million from the issuance and sale of shares of the Company’s common stock and accompanying warrants, before deducting placement agent fees and offering expenses.
-
Cambrex Nears Completion of 5-year, $100-Million-Dollar Investment Plan, One Year Ahead of Schedule
3/18/2024
Cambrex, a leading global contract development and manufacturing organization, announced that it is nearing the completion of a 5-year, $100-million-dollar investment strategy, one year ahead of schedule.
-
Spineart Secures more than CHF20 Million in Convertible Financing Following Completion of BAGUERA®C IDE Studies Enrollment
3/18/2024
Spineart, a global spine specialist working with surgeons to accelerate the adoption of cutting-edge technologies, has successfully raised a CHF20 million convertible financing.
-
Homology Medicines Declares Distribution to Common Stockholders
3/18/2024
Homology Medicines, Inc. announced that it declared a distribution to its common stockholders of record as of the close of business on March 21, 2024 of the right to receive one contingent value right for each outstanding share of Homology common stock held by such stockholder as of such record date.